Updated: Oct 16
Medically reviewed by ChinaCureLink Team
Table of Content
Introduction
Patients researching B-cell non-Hodgkin lymphoma may encounter CAR-T therapy as an emerging cancer immunotherapy option. In China, BRL-201, a CD19-targeted CAR-T product with integrated PD1 regulation, is available through licensed use in Le City, subject to medical evaluation and the applicable clinical-research framework. This guide explains what the treatment is, who may be considered, its estimated cost, where it is offered, and what international patients should know before exploring access.
Key Takeaways |
|
What is B-cell lymphoma CAR-T therapy China?
BRL-201 is a CAR-T cell therapy designed for B-cell malignancies. It targets CD19, a protein found on many B cells, and incorporates PD1 regulation into the CAR-T development process.
The product is developed using the Quikin CART® non-viral site-specific integration platform. This approach is designed to enable stable CAR expression and endogenous PD1 regulation in a single step, without using viral vectors or random genetic integration.
For an international patient, the key point is that this is a personalized cellular immunotherapy rather than a conventional drug taken by mouth or administered as a routine infusion. The treatment process and suitability depend on the patient's diagnosis, previous treatment history, medical records, and assessment by the treating team.
Clinical evidence for BRL-201 remains under evaluation. Its availability through a licensed Le City pathway should therefore be considered separately from evidence about its safety or effectiveness.
B-cell lymphoma CAR-T therapy China: Is It Available?
Yes, BRL-201 is available in China through licensed use in Le City, Hainan, subject to the applicable medical and regulatory requirements.
The treatment is intended for adults with relapsed or refractory B-cell non-Hodgkin lymphoma. As a form of B-cell lymphoma CAR-T therapy in China, BRL-201 is being evaluated for its potential efficacy and safety, while access remains subject to clinical research and licensed-use requirements.
For international patients, this distinction is important: access through a designated Hainan/Le City pathway is not the same as nationwide approval for routine use throughout China. Patients should confirm current eligibility and access arrangements with the treating hospital before making travel plans.
Where Is B-cell Lymphoma CAR-T Therapy Offered?
The treatment is offered at Shanghai Jiao Tong University Affiliated Ruijin Hospital Hainan Hospital (Hainan Boao Research Hospital) in Hainan.
Technical support is provided by Shanghai Bangyao Biotechnology Co., Ltd., and the product is BRL-201.
The product is classified as a moderate- to high-risk medical technology. Current treatment access should therefore be assessed directly with the treating medical team rather than assumed from the availability of the product.
Who May Be Eligible for B-cell Lymphoma CAR-T Therapy China?
The stated eligibility criteria are:
Age 18 or older.
Diagnosis of B-cell non-Hodgkin lymphoma.
Disease that is relapsed or refractory.
Efficacy and safety remain under evaluation, and access is subject to the applicable clinical-research and Le City licensed-use requirements.
Final eligibility is determined by the treating medical team after a face-to-face consultation and review of the patient's medical records.
How Much Does B-cell Lymphoma CAR-T Therapy China Cost?
The estimated cost is ¥480,000 (approximately US$70,800) per session.
For this article, the USD conversion uses approximately ¥6.78 per US$1, based on the September 4, 2026 USD/CNY reference rate.
The stated treatment price does not necessarily include consultation, diagnostic testing, hospitalization, translation or coordination services, medication, or international travel. Patients should confirm the full scope of costs and final pricing directly with the hospital before arranging treatment.
Why International Patients May Consider This B-cell Lymphoma CAR-T Therapy China Option
For some international patients with relapsed or refractory B-cell non-Hodgkin lymphoma, access to a CAR-T therapy through a designated medical-access pathway may provide another option to discuss with qualified specialists.
China's Le City licensed-use framework can provide a route for patients to explore certain medical technologies that are not necessarily available through routine care in every country. However, availability should not be interpreted as proof of superior effectiveness or as a guarantee of an individual outcome.
Patients considering international treatment should compare the proposed therapy with available alternatives, understand the eligibility requirements, and discuss potential benefits and risks directly with qualified physicians.
How ChinaCureLink Can Help Patients Access This Treatment
We help international patients explore available treatment options and facilitate communication with appropriate medical specialists. Patients should discuss potential benefits, risks, eligibility, and alternatives directly with qualified physicians. ChinaCureLink does not represent or endorse the treatment technology, manufacturer, or hospital.
Case review: We collect relevant medical history and B-cell non-Hodgkin lymphoma-management records to help determine whether a case is appropriate for physician review.
Hospital coordination: We help connect patients with the treating team at Shanghai Jiao Tong University Affiliated Ruijin Hospital Hainan Hospital (Hainan Boao Research Hospital) in China for an initial assessment.
Online consultation before travel: Patients can discuss potential eligibility, the procedure, and expected next steps with the medical team remotely before committing to international travel.
Coordination support: Depending on the case, this can include translation assistance, appointment scheduling, and logistics coordination.
Considering This B-cell Lymphoma CAR-T Therapy China Option?
Before planning travel, speak with a qualified specialist to determine whether the treatment is appropriate for your condition and whether you meet the medical eligibility requirements. ChinaCureLink can help international patients arrange a specialist review and explore the treatment pathway in China. [Request a Medical Review / Speak With a Specialist]
Get a Second Opinion Before Fly to China
For suitable cases, ChinaCureLink can then coordinate an online consultation with the specialist to discuss the technical treatment details directly. The purpose is to help the patient understand which treatment option and which specialist center may be most appropriate before making an international treatment decision.
What Patients Say About ChinaCureLink & Medebound HEALTH
China CureLink operates under Medebound HEALTH — an internationally recognized healthcare navigation company incorporated in New York, with operations across North America and Asia-Pacific.
Rated 4.6 ⭐⭐⭐⭐⭐ at Trustpilot
Medebound HEALTH's online testimonials. Learn More
★★★★☆ Sarah Zhang · Canada· Jul 2024 · Verified “The interpreter during the video call was fantastic — super professional and answered all our questions clearly and quickly. The professor was also very patient and gave us detailed and honest guidance on our treatment options.” |
★★★★★ Andrew Goh · Singapore · Aug 2024 · Verified “My first contact with Medebound was over a year ago. Jason has always been responsive, even when I wasn't ready to proceed. When I finally did, the consultation was seamlessly arranged and the specialist was outstanding.” |
★★★★★ Daniel Wong · Singapore · Aug 2024 · Verified “I have dry eye and nothing seemed to be working, even with different medications. I heard about a medication from the U.S. that’s supposed to be really effective, but I didn’t want to try it without talking to a doctor first. MEDEBOUND connected me with a top ophthalmologist in the U.S. and it was so reassuring to get their expert advice.” |
★★★★☆ Pongsakorn · Thailand · Feb 2025 · Verified “Kiki at Medebound is amazing — so professional and helpful! They got my video consultation with an MD Anderson expert set up super fast, within just 5 working days. I am so grateful for their support.” |
Frequently Asked Questions
Is B-cell lymphoma CAR-T therapy available in China?
Yes. BRL-201 is available through licensed use in Le City, Hainan, at Shanghai Jiao Tong University Affiliated Ruijin Hospital Hainan Hospital, subject to medical and applicable regulatory requirements.
How much does B-cell lymphoma CAR-T therapy cost in China?
The estimated cost is US$70,800 (¥480,000) per session. Confirm final pricing and what the quoted price covers directly with the hospital.
Who may qualify for BRL-201 CAR-T therapy?
Adults aged 18 or older with relapsed or refractory B-cell non-Hodgkin lymphoma may be considered. Final eligibility requires medical assessment by the treating team.
Can international patients explore B-cell lymphoma CAR-T therapy in China?
Yes, international patients can explore the treatment pathway through a specialist review. Eligibility and access must be confirmed by the treating hospital before travel.
About ChinaCureLink
ChinaCureLink helps patients across the world access the best cancer treatment at China's top hospitals, without the delays, language barriers, and administrative confusion that typically come with seeking care abroad.
We connect patients directly with China's top cancer hospitals, ensuring that from the first case submission through to treatment and follow-up, every step is guided, translated, and coordinated by a team experienced in cross-border patient care.
ChinaCureLink is proudly affiliated with Medebound HEALTH — founded by US physicians, with over 10 years of experience and more than 3,000 patients served worldwide, Medebound HEALTH is recognized by Forbes and it is one of the most trusted patient cross-border concierge service company across North America and the Asia Pacific.
Disclaimer
This article is for informational purposes only and is not medical or financial advice. Treatment eligibility, protocols, and costs vary by individual case — confirm specifics with a coordinator and treating physician before making any decisions.
